OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
78 hedge funds and large institutions have $257M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
43% more capital invested
Capital invested by funds: $179M → $257M (+$77.7M)
24% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $819K
15% more funds holding
Funds holding: 68 → 78 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.11M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.06M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.55M |
| 4 |
Mitsubishi UFJ Asset Management
Tokyo,
Japan
|
+$1.38M |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.42M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.36M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.3M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.64M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RFA
76
Reilly Financial Advisors
La Mesa,
California
| $3K | – | – | – |
|
|
SSG
77
Summit Securities Group
New York
| $3K | +$2.94K | +116 | New |
|
78
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $234 | +$7.68K | +303 | +3% |
|
|
EC
79
EcoR1 Capital
San Francisco,
California
| – | -$3.42M | -157,038 | Closed |
|
80
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$990K | -45,500 | Closed |
|
|
AP
81
AlpInvest Partners
Amsterdam,
Netherlands
| – | -$489K | -22,450 | Closed |
|
82
Renaissance Technologies
New York
| – | -$450K | -20,675 | Closed |
|
83
AQR Capital Management
Greenwich,
Connecticut
| – | -$263K | -12,100 | Closed |
|
84
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$44K | -2,000 | Closed |
|
OMED Hedge Fund Activity: Q1 2015 in Review
78 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2015, worth a combined $257M — up 43% from $179M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new OMED positions and 6 closed out — a net gain of 10 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $2.11M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.42M sold.
- 78 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2015, up from 68 in Q4 2014.
- Funds reported $257M of OncoMed Pharmaceuticals, Inc. stock for Q1 2015, up 43% quarter-over-quarter.
- 16 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2015 and 6 closed out, a net change of +10 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2015 was JP Morgan Chase, an estimated $2.11M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2015 was EcoR1 Capital, an estimated $3.42M sold.
Based on aggregated 13F filings for Q1 2015.